FibroGen to Present at Upcoming Investor Conferences

Rhea-AI Summary

FibroGen, Inc. (NASDAQ: FGEN) announced that CEO Enrique Conterno will participate in two upcoming healthcare conferences. The first is the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 4:40 PM EST, followed by the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 AM EST. An audio webcast will be available on the company's Investor webpage, with replays accessible for 30 days. FibroGen focuses on developing first-in-class therapeutics, including roxadustat for anemia and pamrevlumab for various disorders.

SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following healthcare conferences:

• Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16 at 4:40 PM EST.
  
• 12^th Annual Jefferies London Healthcare Conference on Thursday, November 18 at 3:00 AM EST.
  

An audio webcast will be available on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days.

About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity for anemia associated with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit www.fibrogen.com.

Contact:
FibroGen, Inc.

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
mtung@fibrogen.com

Media:
Meichiel Keenan
Public Affairs
mkeenan@fibrogen.com

FAQ

What conferences will FibroGen participate in November 2021?

FibroGen will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, and the Jefferies London Healthcare Conference on November 18, 2021.

What is the stock symbol for FibroGen?

The stock symbol for FibroGen is FGEN.

What is roxadustat used for?

Roxadustat is an oral small molecule inhibitor developed by FibroGen for treating anemia associated with chronic kidney disease, myelodysplastic syndromes, and chemotherapy-induced anemia.

When will the FibroGen conference webcasts be available?

The audio webcasts for the conferences will be available on FibroGen's Investor webpage, with replays for approximately 30 days.

Who is the CEO of FibroGen?

The CEO of FibroGen is Enrique Conterno.